Patents by Inventor Kyriacos A. Mitrophanous

Kyriacos A. Mitrophanous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11279954
    Abstract: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1 such that they encode a fusion protein TH-CH1. Also provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding AADC is linked to the nucleotide sequence encoding TH such that they encode a fusion protein AADC-TH or TH-AADC. Further provided is a viral vector comprising such nucleotide sequences and its use in the treatment and/or prevention of Parkinson's disease.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 22, 2022
    Assignee: Oxford BioMedica (UK) Ltd.
    Inventors: Kyriacos A. Mitrophanous, Scott Ralph, Hannah Stewart, Alan John Kingsman
  • Publication number: 20210079360
    Abstract: Disclosed herein are viral vector production systems secreting nuclease for degradation of residual nucleic acid during viral vector production and methods of the same. Such a viral vector production system comprises a viral vector production cell comprising nucleic acid sequences encoding: 1) viral vector components; and 2) a nuclease, wherein the nuclease is expressed in the production cell and secreted in cell culture thereby degrading residual nucleic acid during viral vector production. Another such viral vector production system comprises 1) a viral vector production cell comprising nucleic acid sequences encoding viral vector components; and 2) a nuclease helper cell comprising a nucleic acid sequence encoding a nuclease, wherein the nuclease is expressed and secreted in co-culture of the production cell of 1) and the helper cell of 2), thereby degrading residual nucleic acid during viral vector production.
    Type: Application
    Filed: March 15, 2019
    Publication date: March 18, 2021
    Inventors: Daniel Farley, Kyriacos Mitrophanous
  • Publication number: 20200102578
    Abstract: The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Inventors: Daniel Farley, Kyriacos Mitrophanous
  • Publication number: 20200040361
    Abstract: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1 such that they encode a fusion protein TH-CH1. Also provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding AADC is linked to the nucleotide sequence encoding TH such that they encode a fusion protein AADC-TH or TH-AADC. Further provided is a viral vector comprising such nucleotide sequences and its use in the treatment and/or prevention of Parkinson's disease.
    Type: Application
    Filed: June 26, 2019
    Publication date: February 6, 2020
    Inventors: Kyriacos A. MITROPHANOUS, Scott RALPH, Hannah STEWART, Alan John KINGSMAN
  • Patent number: 10544429
    Abstract: The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 28, 2020
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Daniel Farley, Kyriacos Mitrophanous
  • Patent number: 10400252
    Abstract: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1 such that they encode a fusion protein TH-CH1. Also provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding AADC is linked to the nucleotide sequence encoding TH such that they encode a fusion protein AADC-TH or TH-AADC. Further provided is a viral vector comprising such nucleotide sequences and its use in the treatment and/or prevention of Parkinson's disease.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: September 3, 2019
    Assignee: Oxford BioMedica (UK) Ltd.
    Inventors: Kyriacos A. Mitrophanous, Scott Ralph, Hannah Stewart, Alan John Kingsman
  • Publication number: 20190211358
    Abstract: A cell for producing retroviral vectors comprising nucleic acid sequences encoding: i) gag-pol; ii) env; iii) the RNA genome of the retroviral vector; and iv) optionally rev, or a functional substitute thereof, wherein at least two nucleic acid sequences are located at the same genetic locus; and wherein the at least two nucleic acid sequences are in reverse and/or alternating orientations.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 11, 2019
    Inventors: Hannah Stewart, Helen Maunder, Kyriacos Mitrophanous, Daniel Farley
  • Patent number: 10273502
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 30, 2019
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Patent number: 9738907
    Abstract: Provided is a multicistronic retroviral vector genome having a first nucleic acid sequence upstream of at least one internal regulatory element, such that the level of genomic RNA available for packaging in the absence of rev, or a functional equivalent thereof, is increased.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: August 22, 2017
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Philippa Radcliffe, James E. Miskin, Fraser J. Wilkes, Kyriacos A. Mitrophanous, Susan M. Kingsman
  • Publication number: 20170175135
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.
    Type: Application
    Filed: September 14, 2015
    Publication date: June 22, 2017
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Publication number: 20170073702
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilisation step wherein the filter-sterilisation step is not the final step in the purification process.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 16, 2017
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Publication number: 20160333373
    Abstract: The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an RNA-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 17, 2016
    Inventors: Daniel Farley, Kyriacos Mitrophanous
  • Patent number: 9339512
    Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: May 17, 2016
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Peter Widdowson, Scott Ralph, Kyriacos A. Mitrophanous
  • Patent number: 9169491
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilization step wherein the filter-sterilization step is not the final step in the purification process.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: October 27, 2015
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Publication number: 20130281975
    Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.
    Type: Application
    Filed: May 14, 2013
    Publication date: October 24, 2013
    Inventors: Peter WIDDOWSON, Scott Ralph, Kyriacos A. Mitrophanous
  • Publication number: 20120295960
    Abstract: Provided is an improved treatment for Parkinson's Disease where the efficacy of L-Dopa treatment is increased by including gene therapy in the treatment regimen. The combination therapy results in long-term improvements in response to L-Dopa and diminished side effects caused by L-Dopa.
    Type: Application
    Filed: January 9, 2012
    Publication date: November 22, 2012
    Inventors: Stephane Palfi, Kyriacos A. Mitrophanous, Scott Ralph
  • Publication number: 20110293571
    Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.
    Type: Application
    Filed: May 27, 2011
    Publication date: December 1, 2011
    Applicant: Oxford BioMedica (UK) Ltd.
    Inventors: Peter WIDDOWSON, Scott Ralph, Kyriacos A. Mitrophanous
  • Publication number: 20110269826
    Abstract: The present invention provides methods for: (i) treating and/or preventing Parkinson's disease in a subject without causing cognitive impairment by using dopamine replacement gene therapy to maintain or restore constant physiological dopaminergic tone in both the dorsal and ventral striatum of the subject; (ii) normalising neuronal electrical activity in basal ganglia and/or subthalamic nucleus in a Parkinson's disease subject; and (iii) treating and/or preventing dyskinesias associated with oral L-dopa administration in a Parkinson's disease subject by administration of a vector system for dopamine replacement gene therapy to the subject.
    Type: Application
    Filed: November 11, 2009
    Publication date: November 3, 2011
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Susan M. Kingsman, Alan J. Kingsman, Scott Ralph, Kyriacos A. Mitrophanous, Stephane Palfi, Bechir Jarraya
  • Publication number: 20100273996
    Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pot proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pot proteins is codon optimised for expression in the producer cell.
    Type: Application
    Filed: October 2, 2009
    Publication date: October 28, 2010
    Inventors: Alan John Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos A. Mitrophanous
  • Patent number: 7790419
    Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: September 7, 2010
    Assignee: Oxford Biomedica (UK) Ltd.
    Inventors: Alan John Kingsman, Kyriacos Mitrophanous, Narry Kim